|
CA1247080A
(en)
|
1983-03-08 |
1988-12-20 |
Commonwealth Serum Laboratories Commission |
Antigenically active amino acid sequences
|
|
US5686072A
(en)
|
1992-06-17 |
1997-11-11 |
Board Of Regents, The University Of Texas |
Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
|
|
JP2004508420A
(ja)
|
2000-09-18 |
2004-03-18 |
アイデック ファーマスーティカルズ コーポレイション |
Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
|
|
US7771951B2
(en)
|
2001-12-03 |
2010-08-10 |
Amgen Fremont Inc. |
Antibody categorization based on binding characteristics
|
|
CA2534639C
(en)
|
2003-07-31 |
2013-07-30 |
Immunomedics, Inc. |
Anti-cd19 antibodies
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
CA2611814A1
(en)
|
2005-06-20 |
2007-01-04 |
Medarex, Inc. |
Cd19 antibodies and their uses
|
|
ES2365046T3
(es)
|
2005-12-30 |
2011-09-21 |
Merck Patent Gmbh |
Anticuerpos anti-cd19 con inmunogenicidad reducida.
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
ATE552204T1
(de)
|
2006-08-15 |
2012-04-15 |
Hydralift Amclyde Inc |
Direkt wirkender einzelscheiben-aktiv/passiv- hubkompensator
|
|
RU2495882C2
(ru)
|
2006-09-08 |
2013-10-20 |
Медиммун, Ллк. |
Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
|
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
EP2176298B1
(en)
*
|
2007-05-30 |
2017-11-15 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
DK2211904T3
(en)
|
2007-10-19 |
2016-10-24 |
Seattle Genetics Inc |
Cd19-binding agents and uses thereof
|
|
US20100128586A1
(en)
|
2008-11-25 |
2010-05-27 |
Mediatek Inc. |
Method and apparatus for accessing data from disc with linking area
|
|
CN102421800A
(zh)
|
2009-02-23 |
2012-04-18 |
格兰马克药品股份有限公司 |
结合cd19的人源化抗体及其用途
|
|
US8546399B2
(en)
|
2009-05-26 |
2013-10-01 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
AU2010263272C1
(en)
|
2009-06-24 |
2016-02-11 |
The Feinstein Institute For Medical Research |
Method for treating chronic lymphocytic leukemia
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
CA3007787C
(en)
|
2010-06-03 |
2020-03-10 |
Pharmacyclics Llc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
US8549399B2
(en)
|
2011-01-18 |
2013-10-01 |
Apple Inc. |
Identifying a selection of content in a structured document
|
|
EP2524929A1
(en)
|
2011-05-17 |
2012-11-21 |
Sanofi |
Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
|
|
HRP20220224T1
(hr)
|
2011-08-16 |
2022-04-29 |
Morphosys Ag |
Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
|
|
KR20140064873A
(ko)
|
2011-08-16 |
2014-05-28 |
모르포시스 아게 |
항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
|
|
WO2015082583A1
(en)
*
|
2013-12-05 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
|
|
EP3476392A1
(en)
*
|
2014-02-28 |
2019-05-01 |
Merck Sharp & Dohme Corp. |
Method for treating cancer
|
|
AU2015244039B2
(en)
*
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
AU2015277516A1
(en)
|
2014-06-16 |
2016-12-22 |
Xencor, Inc. |
Treatment for chronic lymphocytic leukemia (CLL)
|
|
MX392487B
(es)
|
2014-10-20 |
2025-03-21 |
Juno Therapeutics Inc |
Métodos y composiciones para dosificación en terapia celular adoptiva.
|
|
CN107406507A
(zh)
*
|
2015-02-12 |
2017-11-28 |
西雅图基因公司 |
使用cd19‑adc和长春新碱的组合疗法
|
|
PE20180454A1
(es)
|
2015-05-26 |
2018-03-05 |
Hoffmann La Roche |
Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2
|
|
LT3302550T
(lt)
|
2015-05-26 |
2019-11-11 |
Morphosys Ag |
Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
|
|
US10973822B2
(en)
|
2015-07-02 |
2021-04-13 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
|
RU2767063C2
(ru)
|
2015-08-21 |
2022-03-16 |
МорфоСис АГ |
Комбинации и их использование
|
|
FI3916392T3
(fi)
|
2016-05-30 |
2024-06-03 |
Incyte Corp |
Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla
|
|
WO2018002031A1
(en)
|
2016-06-27 |
2018-01-04 |
Morphosys Ag |
Anti-cd19 antibody formulations
|
|
US12358983B2
(en)
|
2016-10-28 |
2025-07-15 |
Incyte Corporation |
Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
|
|
LT3630177T
(lt)
|
2017-05-31 |
2023-10-25 |
Morphosys Ag |
Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
|
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
|
KR20200030337A
(ko)
|
2018-09-12 |
2020-03-20 |
주식회사 녹십자랩셀 |
종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
|
|
AU2020267823A1
(en)
|
2019-05-03 |
2021-11-11 |
Incyte Corporation |
Anti-CD19 therapy in patients having a limited number of NK cells
|
|
CN115151565A
(zh)
|
2019-10-31 |
2022-10-04 |
莫佛塞斯公司 |
包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
|
|
TW202525340A
(zh)
|
2019-10-31 |
2025-07-01 |
美商英塞特公司 |
用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
|
|
KR20220104176A
(ko)
|
2019-10-31 |
2022-07-26 |
모르포시스 아게 |
순차적 항-cd19 요법
|
|
WO2021259902A1
(en)
|
2020-06-22 |
2021-12-30 |
Morphosys Ag |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
|
|
WO2022117799A2
(en)
|
2020-12-04 |
2022-06-09 |
Morphosys Ag |
Anti-cd19 combination therapy
|
|
CA3255552A1
(en)
|
2021-12-22 |
2023-06-29 |
Incyte Corporation |
TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY
|